Vunakizumab - CAS 1792181-33-9

Vunakizumab (Anti-Human IL17A Recombinant Antibody) is a human IgGκ monoclonal antibody that specifically targets and inhibits IL-17A's receptor interaction, making it useful for researching autoimmune conditions such as psoriatic arthritis, ankylosing spondylitis, multiple sclerosis, and inflammatory arthritis [1].

IL Receptor, Interleukin

Immunology/Inflammation

1792139

1

-20°C

Ice Packs

Inhibitory Antibodies